Prostaglandin‐E1 infusion in persistent pulmonary hypertension of the newborn
Pediatric Pulmonology · 2024-02 · 59 (2) · 379-388
DOI: 10.1002/ppul.26759 ↗At a glance
Journal article in Pediatric Pulmonology, published online on 2023-11-17. Written by Stephanie M Tsoi and 6 co-authors. Institution: Department of Pediatrics, Division of Critical Care Medicine, University of California San Francisco, San Francisco, California, USA. Major MEDLINE topics: Hypertension, Pulmonary, Persistent Fetal Circulation Syndrome. Cited 9 times so far (Crossref); 28 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: NHLBI NIH HHS, NIH HHS, National Institutes of Health.
Abstract (original language)
Background
Neonates with persistent pulmonary hypertension of the newborn (PPHN) can present with hypoxia and right ventricular dysfunction with resultant inadequate oxygen delivery and end‐organ damage. This study describes the use of prostaglandin‐E1 (PGE) for ductal patency to preserve right ventricular systolic function and limit afterload in newborns with PPHN.
Methods
This is a retrospective cohort study that follows the hemodynamics, markers of end‐organ perfusion, length of therapeutics, and echocardiographic variables of 57 newborns who used prostglandin‐E1 in the setting of PPHN.
Results
Tachycardia, lactic acidosis, and supplemental oxygen use improved following PGE initiation. Fractional area change (FAC), to assess right ventricular systolic function, and pulmonary arterial acceleration time indexed to right ventricular ejection time (PAAT/RVET), to assess right ventricular afterload, also improved over three time points relative to PGE use (before, during, and after).
Conclusions
Overall, we described the safety and utility of PGE in newborns with severe PPHN for stabilization while allowing natural disease progression.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pediatrics, Division of Critical Care Medicine, University of California San Francisco, San Francisco, California, USA.
- Department of Pediatrics, Division of Cardiology, University of California San Francisco, San Francisco, California, USA.
- Department of Pediatrics, Division of Neonatology, University of California San Francisco, San Francisco, California, USA.
- Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.
- Cardiovascular Research Institute, University of California San Francisco, San Francisco, California, USA.
ORCID profiles: Stephanie M Tsoi
Funding
- NHLBI NIH HHS
- NIH HHS
- National Institutes of Health
Cite
APA
Tsoi, S. M., Nawaytou, H., Almeneisi, H., Steurer, M., Zhao, Y., Fineman, J. R., & Keller, R. L. (2024). Prostaglandin‐E1 infusion in persistent pulmonary hypertension of the newborn. Pediatric Pulmonology, 59(2), 379-388. https://doi.org/10.1002/ppul.26759
Vancouver
Tsoi SM, Nawaytou H, Almeneisi H, Steurer M, Zhao Y, Fineman JR, et al. Prostaglandin‐E1 infusion in persistent pulmonary hypertension of the newborn. Pediatric Pulmonology. 2024;59(2):379-388. doi:10.1002/ppul.26759
BibTeX
@article{Tsoi2024,
author = {Tsoi, Stephanie M and Nawaytou, Hythem and Almeneisi, Hassan and Steurer, Martina and Zhao, Yili and Fineman, Jeffrey R and Keller, Roberta L},
title = {Prostaglandin‐E1 infusion in persistent pulmonary hypertension of the newborn},
journal = {Pediatric Pulmonology},
year = {2024},
volume = {59},
number = {2},
pages = {379--388},
doi = {10.1002/ppul.26759}
}
EUVIMED